OHPA has been used in the treatment of a variety of gynecological disorders, including secondary amenorrhea, functional uterine bleeding, infertility, habitual abortion, dysmenorrhea, and premenstrual syndrome. OHPA (100 mg) was reportedly marketed in combination with mestranol (80 μg) as a sequential combined birth control pill under the brand name Hormolidin. The preparation was available in the early 1970s. The firm that manufactured it, known as Gador, was based in Argentina. Available forms
Hydroxyprogesterone acetate
Medroxyprogesterone acetate
Retroprogesterone
Desoxymethyltestosterone
Gestodene
Lipoidal estradiol
Vinyltestosterone
Hydroxyprogesterone caproate